Drug Safety

Use of Enoxaparin in Patients with Chronic Kidney Disease: Safety Considerations
pp. 991-994(4)
Authors: Brophy, Donald F.; Sica, Domenic A.

Benefit-Risk Assessment of Drotrecogin Alfa (Activated) in the Treatment of Sepsis
pp. 995-1010(16)
Author: Daniel De Backer,

Drug-Induced Skin, Nail and Hair Disorders
pp. 1011-1030(20)
Authors: Valeyrie-Allanore, Laurence; Sassolas, Bruno; Roujeau, Jean-Claude

Adverse Drug Reactions in Patients with Phaeochromocytoma: Incidence, Prevention and Management
pp. 1031-1062(32)
Authors: Eisenhofer, Graeme; Rivers, Graham; Rosas, Alejandro L.; Quezado, Zena; Manger, William M.; Pacak, Karel

Drug Interactions with Cholinesterase Inhibitors: An Analysis of the French Pharmacovigilance Database and a Comparison of Two National Drug Formularies (Vidal, British National Formulary)
pp. 1063-1071(9)
Authors: Tavassoli, Neda; Sommet, Agnes; Lapeyre-Mestre, Maryse; Bagheri, Haleh; Montrastruc, Jean-Louis

Factors that Influence Under-Reporting of Suspected Adverse Drug Reactions among Community Pharmacists in a Spanish Region
pp. 1073-1082(10)
Authors: Irujo, Marta; Beitia, Guadalupe; Bes-Rastrollo, Maira; Figueiras, Adolfo; Hernández-Díaz, Sonia; Lasheras, Berta